Beta Finch - S&P 100 - EN

About Beta Finch - S&P 100 - EN

Top 100 US-listed companies by market capitalization. AI-powered earnings call analysis for S&P 100 (SP100). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

Publisher

Beta Finch

Category

business

Language

en

Explicit

No

First episode

17 Feb 2026

Latest episode

29 Oct 2026

Latest episodes

351 episodes in the feed.

1. 

   29 Oct 2026

   Merck Q3 2026 Earnings Analysis

   More earnings analysis: https://betafinch.com (https://betafinch.com) Groups: PHARMA (https://betafinch.com/groups/PHARMA) (https://betafinch.com/groups/PHARMA)) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex. **JORDAN:** And I'm Jordan. Today we're diving into Merck's third quarter 2026 results, reported this past Thursday. **ALEX:** Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Good to have that squared away. So Alex, Merck's a company everyone's watching right now because of the Keytruda patent cliff looming. What'd the quarter actually look like? **ALEX:** Solid, honestly. Revenue came in at $18.1 billion, up 5% year-over-year, or 4% excluding currency effects. And they actually narrowed and raised the midpoint of their full-year guidance — now expecting $66.8 to $67.3 billion in revenue and EPS of $2.77 to $2.82. **JORDAN:** That's a good sign. Companies don't usually raise guidance if they're nervous about the quarter. Let's talk Keytruda specifically, since that's the elephant in the room. **ALEX:** Right, the Keytruda franchise — including the newer subcutaneous version, Keytruda Qlex — grew 6% to $8.6 billion. Still their biggest product by a mile. But management was candid: they're now approaching peak revenues in certain indications, and growth is moderating as they've basically saturated the eligible patient population. **JORDAN:** And that subcutaneous version, Qlex, is actually really interesting as its own story. $830 million in sales this quarter, and there's litigation drama in Europe — a Dutch court issued an injunction over hyaluronidase IP that's blocking sales in several smaller European markets. **ALEX:** Yeah, but CEO Robert Davis was pretty firm that this doesn't change their confidence. The U.S. business is humming — they're targeting 30-40% subcutaneous adoption by end of 2027, and the affected European markets are described as lower-volume anyway. **JORDAN:** Okay, so that's the "today" story. But the real headline for me is what they said about 2027 — because that's when the real Keytruda cliff pressure, plus generic competition for Bridion and Januvia, starts biting. **ALEX:** CFO Caroline Litchfield called it directly: more than $2 billion in headwinds next year from generics hitting Bridion, the Januvia family, and Adempas. Plus continued Keytruda moderation and some German pricing policy pressure. **JORDAN:** But — and this is the part I think investors should really sit with — she described 2027 as "a year of investment," not decline. They're framing the whole Keytruda loss-of-exclusivity period as more of a "hill" in revenue rather than a cliff, with earnings expected to largely mirror that shallow dip and then resume growth. **ALEX:** That's the bet they're making. And it's backed by what might be the most exciting part of this whole call — the pipeline news out of the ESMO oncology conference last weekend. **JORDAN:** Walk us through it, because there were a lot of acronyms flying around. **ALEX:** The biggest one: sac-TMT, their antibody-drug conjugate, showed nearly a 7-month improvement in median overall survival for endometrial cancer patients compared to chemo alone. That's a disease with rising incidence and a really poor prognosis, so that's meaningful. **JORDAN:** And then there's entismodigene — the individualized mRNA cancer vaccine they're developing with Moderna. This one actually got some strong outside validation. **ALEX:** Right,...

2. 

   29 Oct 2026

   Altria Q3 2026 Earnings Analysis

   More earnings analysis: https://betafinch.com (https://betafinch.com) Groups: INCOME (https://betafinch.com/groups/INCOME) (https://betafinch.com/groups/INCOME)) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Altria's third quarter 2026 results, and there's a lot on the table — from a lawsuit against the FDA to a brand-new flavor lineup for nicotine pouches. I'm Alex, here with Jordan, and we're going to break it all down for you. **JORDAN:** Before we get into it — quick reminder, Alex, you know the drill. **ALEX:** Right, right. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Perfect. Okay, let's get into Altria's numbers. **ALEX:** So headline first: adjusted diluted EPS grew 4.8% in Q3, and 5.1% through the first nine months of the year. That's solid growth for a company that's often thought of as slow and steady. **JORDAN:** And here's the thing that jumped out at me — they actually raised guidance. Full-year adjusted EPS is now expected between $5.66 and $5.74, which works out to 4.5% to 6% growth off last year's $5.42. That's up from their original range of 2.5% to 5%. So management is feeling pretty confident here. **ALEX:** Yeah, and that confidence is coming largely from the smokeable products segment, which is still the earnings engine for Altria. Adjusted operating company income there grew 3.9% to $3.1 billion in the quarter. Margins expanded too, up to 64.5%. **JORDAN:** What's interesting is how they're doing it. This isn't just pure pricing power — it's a "total portfolio" strategy. Marlboro's holding the premium end, but they've also got Basic gaining share in the discount segment. Basic's retail share jumped 1.8 points year-over-year as more price-pressured smokers trade down. **ALEX:** And then there's the new kid — Marlboro Cowboy Cut. It's basically a lower-priced premium option designed to keep value-conscious Marlboro smokers in the franchise instead of losing them to discount brands entirely. It's already in about 100,000 stores, roughly 75% of cigarette volume nationally. **JORDAN:** Smart playbook, honestly. They've done this before with Marlboro Special Select and Marlboro Black — launch at an introductory price, then gradually take pricing up over time once it's established. And it seems to be working — Marlboro's share of the premium segment hit 60%, up slightly both year-over-year and sequentially. **ALEX:** Now let's talk about the smoke-free side of the business, because this is where things get really interesting strategically. On! nicotine pouches — shipment volume was up 13.3% in the quarter to 47.8 million cans. **JORDAN:** But retail share only ticked up 0.1 point year-over-year, and was actually down 0.3 sequentially. That tells you this category is getting fiercely competitive. Everybody's throwing flavors and higher nicotine strengths at the wall right now. **ALEX:** Which is exactly what Altria's subsidiary Helix is doing in response — they just rolled out on! PLUS 12-milligram nationally, and they're adding new flavors: Blueberry Mint and Mango Pineapple hit shelves this month, with Watermelon Mint coming in November. **JORDAN:** And don't sleep on the marketing push either — they hosted something called the "on!vitational," an invite-only golf tournament in Palm Beach. It's meant to be a recurring, multiyear brand platform. Altria's clearly trying to build lifestyle equity around on!, not just compete on nicotine strength and flavor. **ALEX:** Now, here's the part of this call I found most...

3. 

   29 Oct 2026

   Mastercard Q3 2026 Earnings Analysis

   More earnings analysis: https://betafinch.com (https://betafinch.com) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, here with Jordan, and today we're diving into Mastercard's third quarter 2026 results. Before we jump in, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** And honestly, there's a lot to unpack here, Alex. Mastercard just put up some seriously strong numbers. **ALEX:** Let's start with the headline figures. Net revenue grew 14% year-over-year on a currency-neutral basis. Net income was up 18%, and EPS jumped 21% to $5.31 a share. **JORDAN:** That EPS number includes about 16 cents from share buybacks — they repurchased $3 billion in stock during the quarter, plus another $648 million through late October. So they're returning serious cash to shareholders while still growing the core business. **ALEX:** Right, and this wasn't a one-trick-pony quarter either. Worldwide gross dollar volume was up 7%, switched transactions grew 9%, cross-border volume jumped 11%. New CFO Ling Hai — this was her very first earnings call, by the way — pointed out that revenue actually came in above expectations, partly because some services projects and deals got pulled forward from Q4 into Q3. **JORDAN:** Which is an important nuance. That timing shift means Q4 might look a touch softer by comparison — not because the business is slowing, but because some of that strength already showed up early. **ALEX:** Let's talk about where the real growth engine is. Value-added services and solutions — things like fraud protection, analytics, consulting, identity — grew 19%. That's now a massive piece of the puzzle. **JORDAN:** And CEO Michael Miebach made a great point: 60% of their services are directly linked to network volume. So as more transactions flow through Mastercard's rails, there's more opportunity to upsell fraud tools, loyalty programs, marketing insights — it's a flywheel. More volume feeds more services, more services make the network stickier, which drives even more volume. **ALEX:** Speaking of new frontiers — agentic commerce was a huge theme on this call. That's basically AI agents shopping on your behalf. **JORDAN:** This was fascinating. Mastercard is pushing hard for something called Agent Pay — fully tokenized transactions where the payment, the agent, and the ecosystem are all verified and trusted. Miebach was really clear that they do NOT want virtual card numbers — VCNs — to become the long-term bridge for agentic payments. He called that just a patchwork solution, not a destination. **ALEX:** And they've already got real partners testing this. Shopify's Shop Pay is using Agent Pay and network tokens. And get this — they signed a broad strategic partnership with OpenAI this quarter. **JORDAN:** That's a big name to have in your corner as agentic commerce scales up. It's early days — Miebach even said the numbers aren't significant yet in the grand scheme — but the weekly growth rates on agentic transactions are apparently impressive. **ALEX:** Another storyline: digital assets and stablecoins. Mastercard closed its acquisition of BVNK during the quarter, and they've already launched a joint product — the Mastercard Global Money Platform. **JORDAN:** This lets banks and fintechs offer accounts where customers can hold, convert, and move between fiat currency and stablecoins, all built on Mastercard's massive money-movement network. Nuvei and Marqeta are already signed on as early adopters. Miebach said almost every conversation with a bank CEO now includes the stablecoin...

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Contact Beta Finch - S&P 100 - EN

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.